Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jun 10

PMID 37296936

Authors

Elettra Merola

Chiara Maria Grana

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells distributed throughout the human body. With an increasing incidence over the past few decades, they represent a highly heterogeneous group of neoplasms, mostly expressing somatostatin receptors (SSTRs) on their cell surface. Peptide receptor radionuclide therapy (PRRT) has emerged as a crucial strategy for treating advanced, unresectable neuroendocrine tumors by administering radiolabeled somatostatin analogs intravenously to target SSTRs. This article will focus on the multidisciplinary theranostic approach, treatment effectiveness (such as response rates and symptom relief), patient outcomes, and toxicity profile of PRRT for NEN patients. We will review the most significant studies, such as the phase III NETTER-1 trial, and discuss promising new radiopharmaceuticals, including alpha-emitting radionuclide-labeled somatostatin analogs and SSTR antagonists.

Citing Articles

Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine.

Shabsigh M, Solomon L Chem Biomed Imaging. 2024; 2(9):615-630.

PMID: 39474267 PMC: 11503725. DOI: 10.1021/cbmi.4c00030.

Radiopharmaceuticals for Pancreatic Cancer: A Review of Current Approaches and Future Directions.

Calistri S, Ottaviano G, Ubaldini A Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458955 PMC: 11510189. DOI: 10.3390/ph17101314.

Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN),....

Panzuto F, Albertelli M, De Rimini M, Rizzo F, Grana C, Cives M J Endocrinol Invest. 2024; 48(1):23-36.

PMID: 39395114 PMC: 11729074. DOI: 10.1007/s40618-024-02448-6.

(SiFA)SeFe: A Hydrophilic Silicon-Based Fluoride Acceptor Enabling Versatile Peptidic Radiohybrid Tracers.

Deiser S, Fenzl S, Konig V, Drexler M, Smith L, George M J Med Chem. 2024; 67(16):14077-14094.

PMID: 39115131 PMC: 11345769. DOI: 10.1021/acs.jmedchem.4c00924.

Neuroendocrine Neoplasia: From Pathophysiology to Novel Therapeutic Approaches.

Carsote M, Nistor C Biomedicines. 2024; 12(4).

PMID: 38672156 PMC: 11048153. DOI: 10.3390/biomedicines12040801.

References

Bodei L, Kidd M, Singh A, van der Zwan W, Severi S, Drozdov I . PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2019; 47(4):895-906. PMC: 7515632. DOI: 10.1007/s00259-019-04601-3. View

Kwekkeboom D, Krenning E, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder W . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009; 90(2):220-6. DOI: 10.1159/000225951. View

Binderup T, Knigge U, Johnbeck C, Loft A, Berthelsen A, Oturai P . F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. J Nucl Med. 2020; 62(6):808-815. PMC: 8729872. DOI: 10.2967/jnumed.120.244798. View

Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7):844-860. DOI: 10.1016/j.annonc.2020.03.304. View

Thang S, Lung M, Kong G, Hofman M, Callahan J, Michael M . Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2017; 45(2):262-277. DOI: 10.1007/s00259-017-3821-2. View

Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G . Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017; 58(2):368-379. PMC: 5671554. DOI: 10.1007/s12020-017-1273-x. View

Hicks R, Kwekkeboom D, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017; 105(3):295-309. DOI: 10.1159/000475526. View

van der Zwan W, Brabander T, Kam B, Teunissen J, Feelders R, Hofland J . Salvage peptide receptor radionuclide therapy with [Lu-DOTA,Tyr]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2018; 46(3):704-717. PMC: 6351514. DOI: 10.1007/s00259-018-4158-1. View

Bakker W, Albert R, Bruns C, Breeman W, Hofland L, Marbach P . [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 1991; 49(22):1583-91. DOI: 10.1016/0024-3205(91)90052-d. View

10.

Severi S, Sansovini M, Ianniello A, Bodei L, Nicolini S, Ibrahim T . Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging. 2015; 42(13):1955-63. DOI: 10.1007/s00259-015-3105-7. View

11.

Pavel M, Valle J, Eriksson B, Rinke A, Caplin M, Chen J . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017; 105(3):266-280. DOI: 10.1159/000471880. View

12.

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M . Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018; 36(25):2578-2584. PMC: 6366953. DOI: 10.1200/JCO.2018.78.5865. View

13.

Sorbye H, Kong G, Grozinsky-Glasberg S . PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer. 2019; 27(3):R67-R77. DOI: 10.1530/ERC-19-0400. View

14.

Merola E, Capurso G, Campana D, Panzuto F, Monarca B, Tomassetti P . Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. Dig Liver Dis. 2009; 42(6):457-8. DOI: 10.1016/j.dld.2009.08.004. View

15.

Merola E, Prasad V, Pascher A, Pape U, Arsenic R, Denecke T . Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options. Neuroendocrinology. 2019; 110(6):517-524. DOI: 10.1159/000503144. View

16.

Kratochwil C, Giesel F, Bruchertseifer F, Mier W, Apostolidis C, Boll R . ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014; 41(11):2106-19. PMC: 4525192. DOI: 10.1007/s00259-014-2857-9. View

17.

Ballal S, Yadav M, Bal C, Sahoo R, Tripathi M . Broadening horizons with Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2019; 47(4):934-946. DOI: 10.1007/s00259-019-04567-2. View

18.

Prise K, OSullivan J . Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009; 9(5):351-60. PMC: 2855954. DOI: 10.1038/nrc2603. View

19.

Parghane R, Bhandare M, Chaudhari V, Ostwal V, Ramaswamy A, Talole S . Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2021; 62(11):1558-1563. PMC: 8612336. DOI: 10.2967/jnumed.120.258772. View

20.

Panzuto F, Merola E, Pavel M, Rinke A, Kump P, Partelli S . Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist. 2017; 22(4):409-415. PMC: 5388376. DOI: 10.1634/theoncologist.2016-0351. View